{"grounding": "Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger, mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is one of the 11 members of the cyclic nucleotide phosphodiesterase (PDE) family that specifically targets cGMP generated by nitric oxide\u2013driven activation of the soluble guanylyl cyclase. PDE5 inhibitors, including sildenafil and tadalafil, are widely used for the treatment of erectile dysfunction, pulmonary arterial hypertension, and certain urological disorders. Preclinical studies have shown promising effects of PDE5 inhibitors in the treatment of myocardial infarction, cardiac hypertrophy, heart failure, cancer and anticancer-drug-associated cardiotoxicity, diabetes, Duchenne muscular dystrophy, Alzheimer's disease, and other aging-related conditions. Many clinical trials with PDE5 inhibitors have focused on the potential cardiovascular, anticancer, and neurological benefits. In this review, we provide an overview of the current state of knowledge on PDE5 inhibitors and their potential therapeutic indications for various clinical disorders beyond erectile dysfunction.", "generated_text": "Phosphodiesterase 5 (PDE5) inhibitors, initially developed for treating erectile dysfunction, have shown promising therapeutic potential beyond their primary indication. This review explores the expanding applications of PDE5 inhibitors in various clinical disorders. By modulating the cGMP signaling pathway, these drugs demonstrate beneficial effects on endothelial function, cardioprotection, and metabolic disorders. Recent studies have also revealed their potential in addressing age-related conditions and certain types of cancer. The pleiotropic effects of PDE5 inhibitors on multiple organ systems highlight their versatility as therapeutic agents. This paper examines the current evidence supporting the use of PDE5 inhibitors in these diverse clinical contexts, discussing their mechanisms of action, efficacy, and safety profiles. The findings suggest that PDE5 inhibitors may offer novel treatment strategies for a wide range of disorders, warranting further investigation into their broader clinical applications.", "label": 1}